Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Clinical trial NCT04514393 · UNKNOWN
Trial details
- NCT number
- NCT04514393
- Sponsor
- Huiqiang Huang
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-10
- Primary completion
- 2022-09-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.